These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells. Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein. Miederer M; Seidl C; Beyer GJ; Charlton DE; Vranjes-Duric S; Comor JJ; Huber R; Nikula T; Apostolidis C; Schuhmacher C; Becker KF; Senekowitsch-Schmidtke R Radiat Res; 2003 May; 159(5):612-20. PubMed ID: 12710872 [TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy with α-particle-emitting radionuclides. Seidl C Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783 [TBL] [Abstract][Full Text] [Related]
5. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735 [TBL] [Abstract][Full Text] [Related]
6. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Kennel SJ; Stabin M; Roeske JC; Foote LJ; Lankford PK; Terzaghi-Howe M; Patterson H; Barkenbus J; Popp DM; Boll R; Mirzadeh S Radiat Res; 1999 Mar; 151(3):244-56. PubMed ID: 10073661 [TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons. Aghevlian S; Boyle AJ; Reilly RM Adv Drug Deliv Rev; 2017 Jan; 109():102-118. PubMed ID: 26705852 [TBL] [Abstract][Full Text] [Related]
14. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129 [TBL] [Abstract][Full Text] [Related]
15. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Rosenblat TL; McDevitt MR; Mulford DA; Pandit-Taskar N; Divgi CR; Panageas KS; Heaney ML; Chanel S; Morgenstern A; Sgouros G; Larson SM; Scheinberg DA; Jurcic JG Clin Cancer Res; 2010 Nov; 16(21):5303-11. PubMed ID: 20858843 [TBL] [Abstract][Full Text] [Related]
16. Advancements in cancer therapy with alpha-emitters: a review. Imam SK Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):271-8. PubMed ID: 11516878 [TBL] [Abstract][Full Text] [Related]
17. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate. Zhang DY; Li Y; Rizvi SM; Qu C; Kearsley J; Allen BJ Cancer Lett; 2005 Feb; 218(2):181-90. PubMed ID: 15670895 [TBL] [Abstract][Full Text] [Related]
19. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells. Xu P; Huang JM; Ren Y; Zha X; Deng BF; Wu JH; Lang JY Chin J Cancer; 2010 Feb; 29(2):126-30. PubMed ID: 20109337 [TBL] [Abstract][Full Text] [Related]
20. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Allen BJ Australas Radiol; 1999 Nov; 43(4):480-6. PubMed ID: 10901964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]